Sage Journals: Discover world-class research

Abstract

The toxicity of polybrominated diphenyl ethers (PBDEs), flame-retardant components, was characterized in offspring from Wistar Han dams exposed by gavage to a PBDE mixture (DE71) starting at gestation day 6 and continuing to weaning on postnatal day (PND) 21. Offspring from the dams underwent PBDE direct dosing by gavage at the same dose as their dams from PND 12 to PND 21, and then after weaning for another thirteen weeks. Liver samples were collected at PND 22 and week 13 for liver gene expression analysis (Affymetrix Rat Genome 230 2.0 Array). Treatment with PBDE induced 1,066 liver gene transcript changes in females and 1,200 transcriptional changes in males at PND 22 (false discovery rate < 0.01), but only 263 liver transcriptional changes at thirteen weeks in male rats (false discovery rate < 0.05). No significant differences in dose response were found between male and female pups. Transcript changes at PND 22 coded for proteins in xenobiotic, sterol, and lipid metabolism, and cell cycle regulation, and overlapped rodent liver transcript patterns after a high-fat diet or phenobarbital exposure. These findings, along with the observed PBDE-induced liver hypertrophy and vacuolization, suggest that long-term PBDE exposure has the potential to modify cell functions that contribute to metabolic disease and/or cancer susceptibilities.

Keywords

polybrominated diphenyl ethers liver toxicity lipid metabolism

Introduction

Polybrominated diphenyl ether (PBDE) flame-retardant exposures are widespread in the United States (Schecter et al. 2010). The PBDEs have physicochemical properties similar to those of other persistent organic chemicals; they are hydrophobic and lipophilic and have a low vapor pressure and a high log K_ow (U.S. Environmental Protection Agency [EPA] 2008a, 2008b, 2008c). There are up to 209 possible isomers of PBDEs. The most common PBDEs found in the environment include PBDE 47, 99, and 153 (EPA 2010; World Health Organization 2003).

The most prevalent PBDE congener found in human tissue is PBDE 47 (Petreas et al. 2003; Schecter et al. 2010; Sjodin et al. 2004). PBDE congeners show long-range atmospheric transport, environmental persistence, and bioaccumulation in various species (including humans) and are considered persistent organic pollutants (POP; World Health Organization 2003).

Environmental exposures come from the use of PBDEs as flame retardants found in polyester foams and other household products. Leaching of PBDEs from these foams deposited at waste dumps may result in the release PBDE isomers into the environment, which may affect water, fish, seals, and humans (Hale et al. 2003; Hale et al. 2002; Hale et al. 2001). The U.S. EPA has recently conducted an exposure assessment for PBDEs and reports that exposure in children (average PBDE intake, 47.2 ng/kg/day) is greater than in adults (average PBDE intake, 7.1 ng/kg/day) (EPA 2010). PBDE exposure to the infant may occur from the mother’s milk (Schecter et al. 2010; Schecter et al. 2006) and house dust (Frederiksen et al. 2010; Harrad et al. 2010; Johnson et al. 2010; Lorber 2008). PBDE exposure is associated with delayed time to pregnancy in women (Harley et al. 2010) and in altered learning parameters in children (Roze et al. 2009).

The European Union banned the use and sale of PBDEs in 2004, and the U.S. manufacturer of PBDEs voluntarily phased out its production in 2004 (EPA 2009). Nevertheless, the potential for PBDE exposures remains a concern because of continued widespread occurrence of these chemicals in the environment, and the long half-life of PBDEs in humans, which is up to six years (EPA 2010).

The biological effects of PBDEs in rodents include thyroid and liver toxicity, developmental neurotoxic effects, and reproductive toxicity (EPA 2008a, 2008b, 2008c). PBDEs disrupt endocrine activity (Hamers et al. 2006; Legler and Brouwer 2003; Meerts et al. 2001), alter thyroid hormone levels (Darnerud et al. 2007; Ellis-Hutchings et al. 2006; Zhou et al. 2002), and induce liver cytochrome p450 levels (Birnbaum and Cohen Hubal 2006; Sanders et al. 2005; Zhou et al. 2002). PBDE-induced toxicities may increase the risk for the development of other diseases (Baker et al. 2007; Ervin 2009; Yanovski and Yanovski 2002). Exposures to PBDEs, nongenotoxic chemicals (Agency for Toxic Substances and Disease Registry 2004), may cause conditions characteristic of those seen in metabolic disease (Lim et al. 2008).

Many PBDE toxicities, including endocrine and liver toxicity, are similar across species (Harley et al. 2010; Roze et al. 2009; EPA 2008a, 2008b, 2008c, 2008d). In this paper we analyze PBDE-induced rat liver toxicity and gene transcript changes to better understand the molecular basis for PBDE toxicities.

Materials and Methods

Chemical

DE-71 (technical pentabromodiphenyl oxide; CAS no. 32534-81-9) was obtained from Great Lakes Chemical Corporation (West Lafayette, IN; Lot 2550OA30A). Components of this mixture included primarily the tetra through penta PBDEs and a small component of hexabromodiphenyl ethers. The molecular weight for tetrabrominated diphenyl ethers is 469.6; for pentabromated diphenyl ethers, 548.5; and for hexabromo diphenyl ethers, 627.4. The DE71 bulk chemical analysis (National Toxicology Program 2004; Sanders et al. 2005) showed the following composition: 2,2′,4,4′-tetrabromodiphenyl ether, PBDE-47 (36%); 2,2′,4,4′,5-pentabromodiphenyl ether, PBDE-99 (42%); 2,2′,4,4′,6-pentabromodiphenyl ether, PBDE-100 (10%); 2,2′,4,4′,5,5′-hexabromodiphenyl ether, PBDE-153 (3%); 2,2′,4,4′,5,6′-hexabromodiphenyl ether, PBDE-154 (4%); and 2,2′,3,4,4′-pentabromodiphenyl ether, PBDE-85 (2%). The remaining 3% consisted of several identified tri-heptaBDEs and some unidentified PBDEs (National Toxicology Program 2004). This flame-retardant mixture also contained approximately 66 ng/g of brominated dioxins or furans. Consequently, a dose of 50 mg/kg is a dose of approximately 3.3 ng/kg body weight of brominated dioxins or furans, a dose not expected to contribute to liver toxicity (National Toxicology Program 2004; Sanders et al. 2005).

Experimental Design

Time-mated female Wistar/Han dams (CRL:WI (HAN)) were obtained from Charles River Laboratories (Raleigh, NC). Dams were dosed by gavage with 0 or 50 mg/kg DE71 in corn oil (dosing volume 5 mL/kg) from gestation day (GD) 6 through postnatal day (PND) 21, seven days per week. Pups were dosed by gavage at the same dose as their dam starting on PND 12 and continuing through PND 21 seven days per week until weaning. Weaning occurred on PND 21, which was designated as day 1 of the thirteen-week portion of the study. On day 1 of the thirteen-week portion of the study, dosing began on a five days/week schedule. Pups used for PND 22 toxicogenomic study were dosed through PND 21, the day prior to PND 22 liver sample collection. Gestational exposure at 50 mg/kg did not affect littering end points for number of dams delivering live litters, number of live or dead pups per litter, or body weights of pups during lactation (data not shown). The NIH 07 diet (Ziegler Brothers, Inc., Gardners, PA) was given to dams and pups throughout the pregnancy and gestation periods and until PND 22, at which time pups were given NTP-2000 diet (Ziegler Brothers). Tap water and NTP-2000 diet were available ad libitum (National Toxicology Program 2005a, 2005b).

On PND 22, liver samples from five male and five female rat pups from the control group and five male and five female rat pups from the 50 mg/kg group were collected for toxicogenomic analysis (each pup came from a different dam, for a total of ten dams from the control group and ten dams from the 50 mg/kg group). Liver samples were collected from ten males and ten females from the control and ten males and ten females from the 50 mg/kg groups for histopathlogic analysis (total of twenty dams from the control group and twenty dams from the 50 mg/kg group). Liver samples from five male rats were randomly selected from each group for the thirteen-week toxicogenomic analysis. No females were sampled for toxicogenomic analysis at thirteen weeks because of possible interference of estrous cycling with interpretation of toxicogenomic findings at this time point.

The care of animals on this study was according to NIH procedures as described in the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals (Office of Laboratory Animal Welfare; April 2002). The study protocols were approved by the local animal care and use committee.

Necropsy and Collection of Liver Samples for Toxcogenomic Analysis

Animals at PND 22 and thirteen weeks were euthanized with carbon dioxide. For liver collection, the abdominal cavity of each rat was opened and the liver removed. A portion of the liver was minced on an ice-cold surface and placed into RNAlater (Ambion, Inc., Austin, TX) for incubation overnight at 4°C. The samples were then transferred to –20°C for storage prior to RNA extraction.

Liver Histopathology

Sections of the livers from the week 13 male rats were fixed in 10% neutral buffer formalin, embedded in paraffin, sectioned at approximately 5 μm, and mounted on glass slides. After staining with hematoxylin and eosin, coverslips were attached to the slides. Tissues were then evaluated microscopically at different magnifications by a board-certified veterinary pathologist.

The grading criteria for hepatocellular hypertrophy was as follows: minimal severity was recorded when hepatocellular hypertrophy was observed but was present in <10% of the hepatocytes in the section; mild severity was recorded when ≥10% and <50% of the hepatocytes in the section were affected; moderate severity was recorded when ≥50% and <75% of the hepatocytes in the section were affected; and marked severity was recorded when ≥75% of the hepatocytes in the section were affected. Cytoplasmic vacuolization was graded independently of hepatocellular hypertrophy according to the following grading scale: minimal severity was recorded when cytoplasmic vacuolization was observed but was present in <25% of the hepatocytes in the section; mild severity was recorded when ≥25% and <50% of the hepatocytes in the section were affected; moderate severity was recorded when ≥50% and <75% of the hepatocytes in the section were affected; and marked severity was recorded when ≥75% of the hepatocytes in the section were affected. Livers from control and treated rats were cryosectioned and stained with Oil Red O to identify the presence of lipids.

RNA Preparation and Microarray Hybridization

A section of the liver was collected at necropsy and placed into RNAlater (Ambion, Inc., Austin, TX). RNA was extracted from liver using the QIAGEN RNeasy (QIAGEN, Valencia, CA). The RNA was analyzed for quantity and purity by UV analysis using the NanoDrop ND-1000 (NanoDropTechnologies, Wilmington, DE). Samples were concentrated using Microcon filters (Millipore, Billerica, MA). All samples were evaluated for RNA integrity by gel electrophoresis using the Flash Gel RNA cassette system (Lonza, Rockland, ME). Total RNA (50 ng) was used to synthesize double-stranded cDNA for each sample using Affymetrix GeneChip® Expression 3′amplication two-cycle target labeling and control reagents (Affymetrix, Inc., Santa Clara, CA). The cDNA served as a template to synthesize biotin-labeled antisense cRNA using an in vitro transcription (IVT) labeling kit. Labeled cRNA was fragmented and hybridized to the Affymetrix Rat Genome 230 2.0 GeneChip Array®. Array hybridization, washing, and staining were performed according to the Affymetrix recommended protocol EuKGE_Ws2v5. The chips were scanned using an Affymetrix GeneChip® Scanner 3000. Quality control measurements were evaluated to determine if the data derived from the arrays were of sufficient quality prior to comparisons for differential expression.

Microarray Data Analysis

Data Normalization

Probe intensity data from all Rat Genome 230 version 2.0 Affymetrix GeneChip® arrays was read into the R software environment (http://www.R-project.org) directly from .CEL files using the R/affy package (Gautier et al. 2004). Probe-level data quality was assessed using image reconstruction, histograms of raw signal intensities, hierarchical clustering of samples, and MvsA plots. Normalization was carried out using the robust multi-array average (RMA) method using all probe intensity data sets together (Irrizarry et al. 2003). Briefly, the RMA method adjusts the background of perfect match (PM) probes, applies a quantile normalization of the corrected PM values, and calculates final expression measures using the Tukey median polish algorithm.

Statistical Assessment of Differential Gene Expression

Analysis of variance (ANOVA) methods were used to statistically resolve gene expression differences using the R/maanova package (Wu et al. 2003). To find differentially expressed probe sets in response to dose, the data were subset into male pups, female pups, or male rats. Then the model

Y_{i} = {μ+DOSE+ε}_{i}

was used to fit the log-transformed gene expression measures Y_i, where μ is the mean for each array, DOSE is the dose effect (control, 50 mg/kg), and ∊_i captures random error. To find sex-related effects in pups, the data were subset into 59 mg/kg dose or control pups and the model

Y_{i} = μ + SEX {+ε}_{i}

was used, where SEX is the sex effect (male, female). To find age-related effects in males, the model

Y = μ+ AGE + DOSE + AGE:DOSE {+ ε}_{i}

was used, where AGE is the effect for age (PND 22, thirteen weeks), DOSE is the dose effect (control, 50 mg/kg), and AGE:DOSE is the interaction effect between age and dose. Finally, to test for sex-dependent responses in dose response, the model

Y_{i} = μ+ SEX {+ DOSE + SEX:DOSE + ε}_{i}

was used, where SEX:DOSE is the interaction effect between sex and dose. All statistical tests were performed using F_s, a modified F statistic incorporating shrinkage estimates of variance components (Cui et al. 2005). P values were calculated by permuting model residuals 1,000 times and corrected using the p.adjust() function in R using method = “BH.”

Gene Ontology Analyses

Overrepresented classifications of genes were determined from statistical outcomes by testing for association with biological process gene ontology (GO) terms. Enrichment of pathway members among differentially expressed probe sets was found using the one-tailed Fisher exact test for 2 × 2 contingency tables. Mappings between Affymetrix probe sets, Entrez gene identifiers, and GO terms are based on the R/rat2302.db package (http://www.bioconductor.org).

Comparison of Gene Transcript Expression to Human Disease

Gene lists and the normalized gene expression estimates (Equations 1–4 above) were compared against results in the literature using the NextBio Platform (Kupershmidt et al. 2010). The NextBio Platform is a Web-based tool to search, discover, and share knowledge using correlation analyses that are able to integrate data across various gene expression platforms and experiments for public and proprietary data. These studies include data sets that have been published and are available in GEO.

Using the NextBio datasets, we compared PND 22 male pup liver transcript data (∼1,200 differentially expressed transcripts; false discovery rate (FDR) < 0.01) to gene transcript patterns in other disease conditions. PBDE transcript patterns were compared to those in rats after phenobarbital exposure (Waterman et al. 2010). Because brominated chemicals induce colon cancers in rodents (Dunnick et al. 1997a), and to further examine the potential of brominated flame retardants to create colon disease susceptibilities, we compared the PBDE transcript patterns to those in human colon cancer gene expression profiles (Ancona et al. 2006; Irizarry et al. 2009; Jorissen et al. 2008; Saaf et al. 2007).

Results

Polybrominated diphenyl ether exposures (DE71) at 50 mg/kg caused no treatment-related effects on survival of rats. Body weight of treated males was 7% greater than controls (p = .13) and 14% lower than controls for females at week 13 (p = 0.002; Table 1 ). Treatment-related liver toxicity and increased liver weights occurred in both sexes (Table 1; Figure 1 ). At week 13, the liver toxicity consisted of hepatocyte hypertrophy characterized by enlarged hepatocytes with an increased amount of cytoplasm, enlarged nuclei, and pale eosinophilic and granular cytoplasm. The hepatocyte hypertrophy was observed primarily in the centrilobular and midzonal regions of the hepatic lobule (lesion not shown).

Figure 2.

Fat accumulation in polybrominated diphenyl ether–treated liver at thirteen weeks (Oil Red O staining of frozen liver sections). (A) Male rat, normal control liver. 10×. (B) Male rat, 50 mg/kg, increase in the amount of fat in the liver of the treated rat, as evidenced by increased red stain. 10×.

Table 1.

Treatment-related effects of polybrominated diphenyl ether, male rats, week 13.

Dose group	Males, 0 mg/kg	Males, 50 mg/kg	Females, 0 mg/kg	Females, 50 mg/kg
Hepatocyte hypertrophy	0/10	10/10 (3.1)^a	0/10	10/10 (2.9)
Hepatocyte vacuolization	3/10 (1.0)	10/10 (1.2)	2/10 (1.0)	4/10 (1.0)
Thyroid gland Follicle hypertrophy	0/10	5/10 (1.2)	0/10	5/10 (1.2)
Mean body weight (g)	403.4	431.2	245.6	213.3
Mean liver weight (g)	13.7 ± 1.24	19.5 ±2.39	7.94± 0.58	9.28 ± 1.35

^a Severity grade.

Hepatocyte cytoplasmic vacuolization was also observed at thirteen weeks in treated rats and consisted of multiple small, variably sized vacuoles or large discrete, singular vacuoles within the cytoplasm of enlarged hepatocytes. Some hepatocytes contained a few scattered, small vacuoles within the cytoplasm, and other heptocytes were distended with numerous small vacuoles in the cytoplasm (microvesicular vacuolization). In addition, scattered large, generally singular but occasionally multiple, clear vacuoles, compatible with macrovesicular vacuolization, were also noted in association with the microvesicular cytoplasmic vacuolization (Figure 1). Hepatocellular cytoplasmic vacuolization was most prominent in the periportal regions. Positive staining with Oil Red O indicated the vesicles within the cells from treated rats contained lipid (Figure 2 ).

Figure 3.

Venn diagram of overlapping significant gene transcripts at PND 22 (males [PMH/PMC] and females [PFH/PFC]), and week 13 (males [RMH/RMC]).

A total of 1,200 differentially expressed transcripts (DETs; control vs. treated animals) were found in male pups, and 1,066 DETS were found in females, at PND 22 (FDR < 0.01). The gene list size for thirteen-week male rats was too small to investigate at FDR < 0.01. However, at an FDR of 0.05, there were 263 DETs in male rats at week 13 (Table 2 and Supplements 1–3). Approximately ninety genes in common were found to be differentially expressed because of PBDE treatment (FDR < 0.05) in PND 22 males, PND 22 females, and week 13 males (Figure 3 ; Supplement 4). Some of the transcripts that were up-regulated at PND 22 and week 13 included aldh1a1, cyp1a1, abcc3, zshhx2, far4, cltb, abhd4, abhd4, ces2, zeint, fam134b, and vps26a. However, at PND 22 there were many more cytochrome P450s up-regulated than at week 13.

Figure 4.

Clustered heat map of biological process gene ontology (GO) terms in up-regulated (red) or down-regulated (green) genes in comparison to PBDE-treated (H) animals to controls (C). Differentially expressed genes for female and male pups (P) were determined by a false discovery rate (FDR) threshold of 0.01, whereas gene lists in thirteen-week-old rats (R) were based on FDR < 0.05. Included processes have p < .05 and at least five differentially expressed genes in at least one comparison. Color key scale indicates the minus log10 p value of GO term significance. Comparisons of female pups (PFH vs PFC), male pups (PMH vs PMC), thirteen-week-old rats (RMH vs RMC).

Table 2.

Number of polybrominated diphenyl ether–induced significant liver gene transcripts.

	Gene list sizes for given false discovery rate
	0.3	0.2	0.1	0.05	0.01	0.001
PBDE male pup^a vs. male pup control	9270	7015	4595	3055	1200	209
PBDE female pup^a vs. female pup control	8178	6264	4113	2832	1066	109
PBDE male rat^b vs. male rat control	3185	1748	611	263	22	0
Male pup control^a vs. female pup control	312	140	25	15	7	7
PBDE male pup^a vs. PBDE female pups	39	26	19	11	9	5
Sex-by-dose (pups)	12	8	0	0	0	0
Age-by-dose (males)	2923	1796	870	447	123	30

Abbreviation: PBDE, polybrominated diphenyl ether.

^aMicroarray sample taken from pups at PND22.

^bMicroarray sample taken from adults at thirteen weeks postweaning.

Note: R statistical analysis.

No sex-dependent differences in gene expression response to PBDEs were found at PND 22 (Table 2; FDR < 0.01). Therefore, we used male PND 22 data to represent the PND 22 profile. With increasing time of PBDE exposure, an adaptive response to the PBDE liver toxicity was suggested by the larger number of DETs found at PND 22 (3,055 DETs FDR < 0.05) than at week 13. A total of 447 age-dependent changes in gene expression response to PBDEs were found here (FDR < 0.05).

Gene ontology analysis (Supplement 5) indicated that gene transcript changes found at PND 22 (Supplements 1 and 2) and week 13 (Supplement 3) are important in multiple cell functions, including oxidative and metabolic functions (Figure 4A). Alterations in transcripts for lipid metabolism were also significant at PND 22 (Table 3B). Many cytochrome P450 transcripts were increased in treated PND 22 pups (Table 3C). PBDE treatment induced alterations in cell cycle gene transcripts and in cancer disease pathways (Table 3D). Up-regulation of the Abcc3 transcript (functions in metabolite conjugation) and glutathione S-transferase α 4 (Gsta4) occurred at both PND 22 and week 13.

Figure 5.

Steps in PBDE toxicity process.

Table 3.

Selected liver gene transcript changes in postnatal day 22 male pup liver.^a

AffyProbe Set ID	Gene symbol	Gene name	Fold change, PBDE male pups vs. male controls	Fold change, PBDE female pups vs. female controls
A. Up-regulation of genes combating oxidative stress
1387958_at	Akr1c18	Aldo-keto reductase family 1, member C18	2.38	1.78
1371997_at	Akr1cl2	Aldo-keto reductase family 1, member C-like 2	1.34	1.24
1398310_at	Akr1d1	Aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-beta-reductase)	1.42	1.16
1367843_at	Akr7a2	Aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase)	1.39	1.46
1368121_at	Akr7a3	Aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)	3.04	2.40
1387022_at	Aldh1a1	Aldehyde dehydrogenase 1 family, member A1	2.84	2.87
1368718_at	Aldh1a7	Aldehyde dehydrogenase family 1, subfamily A7	2.78	2.65
1368130_at	Aldh3a1	Aldehyde dehydrogenase 3 family, member A1	1.88	4.81
1368037_at	Cbr1	Carbonyl reductase 1	1.43	1.52
1367774_at	Gsta3	Glutathione S-transferase A3	1.30	1.22
1372297_at	Gsta4	Glutathione S-transferase alpha 4	2.45	2.27
1386985_at	Gstm1	Glutathione S-transferase mu 1	1.70	1.71
1370952_at	Gstm2	Glutathione S-transferase mu 2	2.65	2.02
1369921_at	Gstm3	Glutathione S-transferase mu 3	2.01	1.71
1375909_at	Gstm4	Glutathione S-transferase mu 4	1.74	1.77
1368354_at	Gstt1	Glutathione S-transferase theta 1	1.74	1.62
1371942_at	Gstt3	Glutathione S-transferase, theta 3	1.96	1.73
1372599_at	Mgst2	Microsomal glutathione S-transferase 2	1.45	1.46
B. Genes in lipid metabolism/metabolic syndrome
1368126_at	Aacs	Acetoacetyl-CoA synthetase	−3.51	−2.70
1369455_at	Abcg5	ATP-binding cassette, sub-family G (WHITE), member 5	−4.57	−4.24
1368718_at	Aldh1a7	Aldehyde dehydrogenase family 1, subfamily A7	2.78	2.65
1369727_at	Apoa2	Apolipoprotein A-II	3.64	3.79
1369011_at	Apoa5	Apolipoprotein A-V	−1.50	−1.60
1393139_at	Apoc2	Apolipoprotein C-II	−1.23	−1.11
1386901_at	Cd36	CD36 molecule (thrombospondin receptor)	1.66	−1.06?
1367689_a_at	Cd36	CD36 molecule (thrombospondin receptor)	1.26	–
1384341_at	Faah	Fatty acid amide hydrolase	−1.52	–
1393751_at	Fabp12	Fatty acid binding protein 12	−1.62	–
1370281_at	Fabp5	Fatty acid binding protein 5, epidermal	−2.84	–
1370024_at	Fabp7	Fatty acid binding protein 7, brain	−1.38	–
1368453_at	Fads2	Fatty acid desaturase 2	−2.97	−1.94
1372476_at	Fads3	Fatty acid desaturase 3	1.56	–
1367707_at	Fasn	Fatty acid synthase	−2.99	–
1367708_a_at	Fasn	Fatty acid synthase	−2.17	–
1373491_at	Gba	Glucosidase, beta, acid	1.44	1.34
1370200_at	Glud1	Glutamate dehydrogenase 1	−1.46	–
1373222_at	Hexa	Hexosaminidase A	1.32	–
1375852_at	Hmgcr	3-hydroxy-3-methylglutaryl-coenzyme A reductase	−1.70	–
1387848_at	Hmgcr	3-hydroxy-3-methylglutaryl-coenzyme A reductase	−1.78	–
1367648_at	Igfbp2	Insulin-like growth factor binding protein 2	−5.17	−2.51
1367887_at	Lcat	Lecithin cholesterol acyltransferase	−1.14	–
1381672_at	Ldlrap1	Low-density lipoprotein receptor adaptor protein 1	1.10	–
1386965_at	Lpl	Lipoprotein lipase	7.13	4.71
1369150_at	Pdk4	Pyruvate dehydrogenase kinase, isozyme 4	1.88	–
1386864_at	Pgam1	Phosphoglycerate mutase 1 (brain)	1.25	1.26
1387803_at	Ppp2r2b	Protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform	−4.83	−6.34
1371143_at	Serpina7	Serine (or cysteine) peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 7	−4.53	−4.44
1387325_at	Slc27a5	Solute carrier family 27 (fatty acid transporter), member 5	−1.56	−1.49
1369636_at	Sord	Sorbitol dehydrogenase	1.29	–
1394786_at	Sorl1	Sortilin-related receptor, LDLR class A repeats-containing	−1.44	–
1393933_at	Sorl1	Sortilin-related receptor, LDLR class A repeats-containing	−1.44	–
1371104_at	Srebf1	Sterol regulatory element binding transcription factor 1	−1.87	–
1371979_at	Srebf2	Sterol regulatory element binding transcription factor 2	−1.31	–
1367938_at	Ugdh	UDP-glucose dehydrogenase	1.67	1.49
1389611_at	Vldlr	Very low-density lipoprotein receptor	−1.03	1.32
C. Cytochrome P450s
1369136_at	Cyp2a3a	Cytochrome P450, family 2, subfamily A, polypeptide 3a	37.40	6.84
1370269_at	Cyp1a1	Cytochrome P450, family 1, subfamily a, polypeptide 1	26.68	39.63
1370241_at	Cyp2c7	Cytochrome P450, family 2, subfamily c, polypeptide 7	23.68	9.17
1370495_s_at	Cyp2c13	Cytochrome P450 2c13	21.10	–
1387328_at	Cyp2c	Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase)	6.99	2.45
1368990_at	Cyp1b1	Cytochrome P450, family 1, subfamily b, polypeptide 1	4.95	10.96
1370387_at	Cyp3a9	Cytochrome P450, family 3, subfamily a, polypeptide 9	2.95	–
1387243_at	Cyp1a2	Cytochrome P450, family 1, subfamily a, polypeptide 2	2.24	2.13
1387118_at	Cyp3a23/3a1	Cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1	1.97	2.03
1369424_at	Cyp2a2	Cytochrome P450, subfamily 2A, polypeptide 1	1.77	–
1387511_at	Cyp2a1	Cytochrome P450 IIA1 (hepatic steroid hydroxylase IIA1) gene	1.64	–
1368155_at	Cyp2c12	Cytochrome P450, family 2, subfamily c, polypeptide 12	1.52	–
1387296_at	Cyp2j4	Cytochrome P450, family 2, subfamily J, polypeptide 4	1.46	–
1387296_at	Cyp2j4	Cytochrome P450, family 2, subfamily J, polypeptide 4	1.46	–
1387973_at	Cyp4f4	Cytochrome P450, family 4, subfamily f, polypeptide 4	1.28	–
1371142_at	Cyp2g1	Cytochrome P450, subfamily 2G, polypeptide 1	−1.03	–
1368458_at	Cyp7a1	Cytochrome P450, family 7, subfamily a, polypeptide 1	−2.30	–
1368435_at	Cyp8b1	Cytochrome P450, family 8, subfamily b, polypeptide 1	−2.93	−4.20
1387123_at	Cyp17a1	Cytochrome P450, family 17, subfamily a, polypeptide 1	−6.16	−5.23
1371076_at	Cyp2b	Cytochrome P450, family 2b	6.13	9.96
D. Cell cycle/cancer
1369698_at	Abcc3	ATP-binding cassette, sub-family C (CFTR/MRP), member 3	3.23	3.23
1379652_at	Ahctf1	AT hook containing transcription factor 1	−1.54	–
1379652_at	Ahctf1	AT hook containing transcription factor 1	−1.54	–
1369983_at	Ccl5	Chemokine (C-C motif) ligand 5	2.21	2.02
1370345_at	Ccnb1	Cyclin B1	1.94	–
1389566_at	Ccnb2	Cyclin B2	1.78	–
1371643_at	Ccnd1	Cyclin D1	−2.13	–
1371150_at	Ccnd1	Cyclin D1	−2.28	−1.94
1383075_at	Ccnd1	Cyclin D1	−2.33	−2.1
1370810_at	Ccnd2	Cyclin D2	−1.42	–
1371953_at	Ccng2	Cyclin G2	2.33	–
1380997_at	Ccnj	Cyclin J	−1.51	–
1374220_at	Ccny	Cyclin Y	1.33	–
1372685_at	Cdkn3	Cyclin-dependent kinase inhibitor 3	1.79	–
1387062_a_at	Chek1	CHK1 checkpoint homolog (S. pombe)	2.90	3.89
1367515_at	Cnot7	CCR4-NOT transcription complex, subunit 7	−1.31	–
1367515_at	Cnot7	CCR4-NOT transcription complex, subunit 7	−1.31	–
1368174_at	Egln3	EGL nine homolog 3 (C. elegans)	4.43	4.89
1373011_at	Fam134b	Family with sequence similarity 134, member B	4.34	3.87
1368408_at	Grk5	G protein-coupled receptor kinase 5	3.28	2.95
1368549_at	Hbp1	HMG-box transcription factor 1	1.30	–
1368549_at	Hbp1	HMG-box transcription factor 1	1.30	–
1370728_at	Il13ra1	Interleukin 13 receptor, alpha 1	1.73	–
1388711_at	Il13ra1	Interleukin 13 receptor, alpha 1	1.47	–
1371170_a_at	Il1a	Interleukin 1 alpha	−1.37	−1.59
1368592_at	Il1a	Interleukin 1 alpha	−1.75	–
1387394_at	Il2rb	Interleukin 2 receptor, beta	1.50	–
1387935_at	Il3ra	Interleukin 3 receptor, alpha	1.39	1.34
1386987_at	Il6ra	Interleukin 6 receptor, alpha	−1.33	–
1373379_at	Irak1	Interleukin-1 receptor-associated kinase 1	1.32	–
1380336_at	Irak3	Interleukin-1 receptor-associated kinase 3	1.50	–
1368915_at	Kmo	Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	−1.54	−0.02
1371479_at	Mettl7a	Methyltransferase like 7A	1.90	1.54
1384280_at	Nusap1	Nucleolar and spindle associated protein 1	1.59	–
1392715_at	Ppargc1b	Peroxisome proliferator-activated receptor gamma, coactivator 1 beta	−1.82	–
1370012_at	Ptgis	Prostaglandin I2 (prostacyclin) synthase	−3.10	−3.19
1398814_at	Rab11a	RAB11a, member RAS oncogene family	1.40	1.37
1389066_at	Rcan2	Regulator of calcineurin 2	2.10	2.15
1378605_at	Sigirr	Single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	1.32	–
1379275_at	Snx10	Sorting nexin 10	3.96	5.49
1371104_at	Srebf1	Sterol regulatory element binding transcription factor 1	−1.87	–
1388426_at	Srebf1	Sterol regulatory element binding transcription factor 1	−1.94	–
1367941_at	Tfam	Transcription factor A, mitochondrial	1.04	–
1376668_at	Ttc39a	Tetratricopeptide repeat domain 39A	8.84	14.87

Abbreviation: PBDE, polybrominated diphenyl ether.

^a False discovery rate < 0.01; p < .01 for all gene transcripts in this table (complete details in supplements 1 and 2). Most of these gene transcripts were not significantly changed in week 13 male rat livers.

After scrutinizing the expression pattern of important genes (described above), PND 22 transcript data were subjected to a global bioinformatics analysis using NextBio software to compare the expression profiles obtained in this study to expression profiles found in the literature. PBDE liver gene transcript patterns correlated with other rodent studies on high-fat diets, including upregulation of cyp2c7, ces2, lpl, cyp2c, cyp2b2 (Almon et al. 2009; van Erk 2011). PBDE transcript patterns correlated with liver transcript patterns after phenobarbital exposure (rats; Supplement 6), with 67 up-regulated transcripts and 164 down-regulated transcripts that overlapped those in phenobarbital-treated rats, including up-regulation (>4 fold) of transcripts for P450, chemokine, carboxyesterase, and growth arrest activity (cyp1a1, cxcl9, ces2, zdhhc2, lpl, cyp2b2, rn71071, cyp1b1, egin3, and gadd45b).

PBDE transcript patterns were similar to some of the changes found in human cancers, including colon cancers (Supplement 7). Transcripts up-regulated in human colon cancer and after PBDE treatment included cyp2b6, fam134b, chek1, rcan2, ccng2, ccl5, and acacb.

Discussion

In utero/postnatal exposure of Wistar Han rats starting on GD 6 (start of organogenesis) to a mixture of low-molecular-weight polybrominated diphenyl ethers (PBDEs) resulted in liver toxicity characterized by hepatocyte hypertrophy and hepatocyte cytoplasmic vacuolization. This liver toxicity in the Wistar Han rat is similar to that observed in the F344/N rat after PBDE exposure (Dunnick and Nyska 2009). Hepatocellular vacuolization, as seen in PBDE rat livers, is often indicative of accumulation of fat deposits (Eustis et al. 1990). Nonalcoholic fatty liver is a hepatic manifestation of the metabolic syndrome (Lucero et al. 2010) and a common cause of liver enzyme elevation in humans and in rats (Stickel and Hellerbrand 2010).

The occurrence of hepatocellular hypertrophy and vacuolization may predispose rats to liver cancer. However, not all exposures that result in these liver histopathologic features lead to liver cancer (Maronpot et al. 2010). From a review of NTP chemical study findings at ninety days, only 45% of rats studied with chemical-induced liver hypertrophy went on to have liver carcinogens in two-year cancer studies (Allen et al. 2004). Thus, there is a need for additional biomarkers to predict disease.

PBDE-induced liver gene transcript changes modify cell pathways and functions that, along with the liver toxicity, may lead to disease susceptibilities. These changes include alterations in lipid and metabolic pathways. For instance, at PND 22, PBDE increased the transcript for lipoprotein lipase seven-fold versus that in untreated liver. An increase in lipoprotein lipase activity has been associated with diabetes and metabolic diseases (Lopaschuk et al. 2010). PBDE decreased the cyp7a transcript, which codes for an enzyme critical in the metabolism of cholesterol to bile acids and in controlling hepatic triglyceride levels (Lee et al. 2010). The PBDE transcript patterns reported here support other findings, which show that PBDE exposures lead to increased body weights in rodents and alterations in adipocyte metabolism (Hoppe and Carey 2007; Suvorov and Takser 2010).

Thyroid homeostasis is important in preventing metabolic, reproductive, developmental, and cardiac disease (Choksi et al. 2003; Jahnke et al. 2004; Miller et al. 2009; Pedrelli et al. 2010). PBDE-induced alterations in thyroid hormone levels (Dunnick and Nyska 2009; Richardson et al. 2008) may affect mitochondria biogenesis (Leigh-Brown et al. 2010) or alter mitochondria-based TCA cycle and lipid distribution (Harper and Seifert 2008). Liver gene transcript analysis in the current study supports a finding of altered lipid metabolism. A PBDE-induced effect on lipid metabolism, along with PBDE-induced endocrine effects, may create susceptibilities to metabolic diseases.

The PBDE-induced liver toxicity was accompanied by increases in liver P450 transcripts—including those for cyp2a3a, cyp1a1 cyp1b1, cyp2c7, cyp2c13, cyt2c, and cyp2b—coding for enzymes critical in the metabolism of chemicals, drugs, fatty acids, and steroids (Yang et al. 2010). Up-regulation of these cytochrome P450 liver enzymes has been found with other chemicals that cause fatty liver, or steatosis (Lee et al. 2008; Lee et al. 2010), and is associated with the development of carcinogenic events (Rendic and Guengerich 2010). An adaptive response to the PBDE liver toxicity was suggested by fewer significant liver gene transcript changes at week 13 than at PND 22, and induced liver transcripts for enzymes involved in decreasing aldehyde loads (Ellis 2007), which may be part of an adaptive response to toxicity.

PBDE and dioxin exposures are both associated with increases in liver P450 enzyme levels (Boverhof, Burgoon et al. 2006; Boverhof, Kwekel et al. 2006; N’Jai et al. 2008; Sanders et al. 2005; Szabo et al. 2009) and may involve activation of AH, PXR, or CAR receptors (Szabo et al. 2009). The PBDE mixture used in our studies contained a low level of brominated dioxins and furans that by themselves would not be expected to cause cancers (Dunnick and Nyska 2009), but in combination with the PBDEs may have synergistic carcinogenic effects. Whether that occurred in our studies would require further investigation.

Other studies report the PBDE exposures increase expression of genes coding for liver enzymes, including cyp2B, hepatic deiodinase 1 protein (D1) activities and cyp2b1, d1, and hepatic efflux transporter gene expression (mdr1, mrp2, mrp3) in rats at PND4, PND21, and PND60 (Szabo et al. 2009). Not all of these liver gene transcripts were up-regulated in our PBDE studies, although a different strain of rat (Long Evans rat) was used in the Szabo et al. (2009) studies.

The liver gene expression profile generated by PBDE at PND 22 was similar to the transcriptional profile produced by phenobarbital in rodents (Nesnow et al. 2009; Waterman et al. 2010). Phenobarbital is a chemical that induces liver tumors in rodents (Butler 1978; Imaida and Wang 1986; Rossi et al. 1977). The changes include transcript abundance increases for P450s, chemokines, carboxylesterases, and growth factor arrest (gadd45b) gene transcript levels, and were similar to liver gene transcript patterns found in human liver cancers (Frau et al. 2010; Tanaka and Arii 2010; Teoh 2009).

Liver genotoxic carcinogens are characterized by a specific liver fingerprint after fourteen days or thirteen weeks of exposure (up-regulaton of mybl2, cyp1A1, and adam8 and down-regulation of wwox, fhit, RGD1561899) (Auerbach et al. 2009). This “genotoxic chemical” fingerprint was not seen with PBDE exposure, except for the up-regulation of cyp1A1. Based on these findings, the PBDE liver toxic mechanisms appear to differ from those of genotoxic liver toxins.

PBDE liver transcript patterns include those found in metabolic disease conditions. Metabolic disease conditions may contribute to the development of cancer (e.g., colorectal or uterine cancer) or heart disease, particularly when either one occurs in combination with other underlying genetic conditions or environmental exposures (Lopaschuk et al. 2010).

PBDE liver gene transcript patterns overlapped those seen in human cancer (colon), including up-regulation of cyclins (Koliadi et al. 2010) and other cell cycle controls (Stephens et al. 2011). In other studies, we reported that brominated chemicals may have a particular propensity to cause intestinal tumors (Dunnick et al. 1997b). Bromide radical formation in the intestine resulting in DNA damage (Ballmaier and Epe 2006) is one hypothesis for the cause of a brominated chemical carcinogenic response in the intestine, and additional studies would be needed to determine whether this cancer occurs after long-term PBDE exposure.

PBDE treatment decreased expression of cyp17a1, a decrease that is associated with blocking androgen production (Hofland et al. 2010) and altering sex steroidogenesis (Canton et al. 2006). PBDE transcript patterns associated with alterations in the endocrine system are consistent with the ability of PBDEs to cause MCF7 cell proliferation (Darnerud 2008; Mercado-Feliciano and Bigsby 2008a, b; Song et al. 2008; Talsness et al. 2008). In addition, PBDE is an ER α and β agonist in human T47D breast cancer cell lines (Meerts et al. 2001).

PBDE and its metabolites (e.g., 6-OH-BDE47) may increase reactive oxygen species leading to lipid peroxidation, aldehyde formation, and DNA adduct formation (An et al. 2010; Jin et al. 2010). For these reasons, PBDE exposure could contribute to the development of carcinogenesis processes, as suggested by our findings (Figure 5 ).

Figure 1.

Photomicrographs of control and polybrominated diphenyl ether–treated livers at thirteen weeks. (A) Male rat, normal control liver. Hematoxylin and eosin, 600×. (B) Male rat, 50 mg/kg, microvesicular vacuolization of hepatocytes (blue arrows); macrovesicular vacuolization of hepatocytes (black arrows). Hematoxylin and eosin, 600×.

The liver gene transcript changes observed in this study suggest that PBDE exposure could lead to disease susceptibilities including those for metabolic/lipid disease (e.g., lipoprotein lipase [lpl]), cancer (e.g., cell cycle control transcripts [cyclins] or chemokine transcripts), and sex hormone synthesis (cyp17).

Footnotes

Supplemental files are located online at .

SUPPLEMENT 1.—Liver gene transcript changes, PND 22 males.

SUPPLEMENT 2.—Liver gene transcript changes, PND 22 females.

SUPPLEMENT 3.—Liver gene transcript changes, week 13 males.

SUPPLEMENT 4.—PBDE significant genes at PND 22 and week 13.

SUPPLEMENT 5.—GO analysis.

SUPPLEMENT 6.—PBDE PND 22 male liver gene transcripts versus phenobarbital gene transcript changes (developed from Nextbio database).

SUPPLEMENT 7.—PBDE PND 22 male liver gene transcripts versus human colon cancer genes (developed from Nextbio database).

Online supplemental material is available at .

This work was supported by the intramural program of the National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC. However, the statements, opinions, or conclusions contained therein do not necessarily represent the statements, opinions, or conclusions of NIEHS, NIH or the United States government. The in-life portion of this study was conducted under the supervision of Dr. C. Hébert, Southern Research Institute, under NIEHS contract NO1-ES-45516 and the microarray analysis under contract N01-ES-55536. Statistical support was provided under NIEHS contract ES 55547. We thank G. Kissling, A. Merrick, and M. Sanders, NIEHS, for their review of the manuscript.

Abbreviations

References

Agency for Toxic Substances and Disease Registry (2004). Toxicological Profile for Polybrominated Biphenyls and Polybrominated Diphenyl Ethers (PBBs and PBDEs). http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=529&tid=94. Accessed April 2011.

Allen

D. G.

Pearse

Haseman

J. K.

Maronpot

R. R.

(2004). Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol 32, 393–401.

Almon

R. R.

DuBois

D. C.

Lai

Xue

Nie

Jusko

W. J.

(2009). Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats. J Endocrinol 200, 331–46.

Zhong

Wang

Zhen

Zhang

Sheng

Huang

. (2010). The cytotoxic effects of synthetic 6-hydroxylated and 6-methoxylated polybrominated diphenyl ether 47 (BDE47). Environ Toxicol [Epub ahead of print].

Ancona

Maglietta

Piepoli

D’Addabbo

Cotugno

Savino

Liuni

Carella

Pesole

Perri

(2006). On the statistical assessment of classifiers using DNA microarray data. BMC Bioinformatics 7, 387.

Auerbach

S. S.

Shah

R. R.

Mav

Smith

C. S.

Walker

N. J.

Vallant

M. K.

Boorman

G. A.

Irwin

R. D.

(2009). Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol 243, 300–14.

Baker

J. L.

Olsen

L. W.

Sorensen

T. I.

(2007). Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 357, 2329–37.

Ballmaier

Epe

(2006). DNA damage by bromate: Mechanism and consequences. Toxicology 221, 166–71.

Birnbaum

L. S.

Cohen Hubal

E. A.

(2006). Polybrominated diphenyl ethers: A case study for using biomonitoring data to address risk assessment questions. Environ Health Perspect 114, 1770–75.

10.

Boverhof

D. R.

Burgoon

L. D.

Tashiro

Sharratt

Chittim

Harkema

J. R.

Mendrick

D. L.

Zacharewski

T. R.

(2006). Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol Sci 94, 398–416.

11.

Boverhof

D. R.

Kwekel

J. C.

Humes

D. G.

Burgoon

L. D.

Zacharewski

T. R.

(2006). Dioxin induces an estrogen-like, estrogen receptor-dependent gene expression response in the murine uterus. Mol Pharmacol 69, 1599–606.

12.

Butler

W. H.

(1978). Long-term effects of phenobarbitone-Na on male Fischer rats. Br J Cancer 37, 418–23.

13.

Canton

R. F.

Sanderson

J. T.

Nijmeijer

Bergman

Letcher

R. J.

van den Berg

. (2006). In vitro effects of brominated flame retardants and metabolites on CYP17 catalytic activity: a novel mechanism of action? Toxicol Appl Pharmacol 216, 274–81.

14.

Choksi

N. Y.

Jahnke

G. D.

St. Hilaire

Shelby

(2003). Role of thyroid hormones in human and laboratory animal reproductive health. Birth Defects Res B Dev Reprod Toxicol 68, 479–91.

15.

Cui

Hwang

J. T.

Qiu

Blades

N. J.

Churchill

G. A.

(2005). Improved statistical tests for differential gene expression by shrinking variance components estimates. Biostatistics 6, 59–75.

16.

Darnerud

P. O.

(2008). Brominated flame retardants as possible endocrine disrupters. Int J Androl 31, 152–60.

17.

Darnerud

P. O.

Aune

Larsson

Hallgren

(2007). Plasma PBDE and thyroxine levels in rats exposed to Bromkal or BDE-47. Chemosphere 67, S386–92.

18.

Dunnick

J. K.

Heath

J. E.

Farnell

D. R.

Prejean

J. D.

Haseman

J. K.

Elwell

M. R.

(1997a). Carcinogenic activity of the flame retardant, 2,2-bis(bromomethyl)-1,3-propanediol in rodents, and comparison with the carcinogenicity of other NTP brominated chemicals. Toxicol Pathol 25, 541–48.

19.

Dunnick

Heath

Farnell

Prejean

Haseman

Elwell

M. R.

(1997b). Carcinogenic activity of the flame retardant, 2,2-bis(bromomethyl)-1,3-propanediol in rodents, and comparison with the carcinogenicity of other NTP brominated chemicals. Toxicol Pathol 25, 541–48.

20.

Dunnick

J. K.

Nyska

(2009). Characterization of liver toxicity in F344/N rats and B6C3F1 mice after exposure to a flame retardant containing lower molecular weight polybrominated diphenyl ethers. Exp Toxicol Pathol 61, 1–12.

21.

Ellis

E. M.

(2007). Reactive carbonyls and oxidative stress: Potential for therapeutic intervention. Pharmacol Ther 115, 13–24.

22.

Ellis-Hutchings

R. G.

Cherr

G. N.

Hanna

L. A.

Keen

C. L.

(2006). Polybrominated diphenyl ether (PBDE)-induced alterations in vitamin A and thyroid hormone concentrations in the rat during lactation and early postnatal development. Toxicol Appl Pharmacol 215, 135–45.

23.

Ervin

R. B.

(2009). Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report 5, 1–7.

24.

Eustis

S. L.

Boorman

G. A.

Harada

Popp

J. A.

(1990). Liver. In Pathology of the Fischer Rat ( Boorman

G. A.

Eustis

S. L.

Elwell

M. R.

Montgomery

C. A.

Jr. MacKenzie

W. F.

, eds.), pp. 78–81. Academic Press Inc., New York, NY.

25.

Frau

Biasi

Feo

Pascale

R. M.

(2010). Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med 31, 179–93.

26.

Frederiksen

Thomsen

Froshaug

Vorkamp

Thomsen

Becher

Knudsen

L. E.

(2010). Polybrominated diphenyl ethers in paired samples of maternal and umbilical cord blood plasma and associations with house dust in a Danish cohort. Int J Hyg Environ Health 213, 233–42.

27.

Gautier

Cope

Bolstad

B. M.

Irizarry

R. A

. (2004). affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307–15.

28.

Hale

R. C.

Alaee

Manchester-Neesvig

J. B.

Stapleton

H. M.

Ikonomou

M. G.

(2003). Polybrominated diphenyl ether flame retardants in the North American environment. Environ Int 29, 771–79.

29.

Hale

R. C.

La Guardia

M. J.

Harvey

Mainor

T. M.

(2002). Potential role of fire retardant-treated polyurethane foam as a source of brominated diphenyl etheres to the U. S. environment. Chemosphere 46, 729–35.

30.

Hale

R. C.

La Guardia

M. J.

Harvey

E. P.

Gaylor

M. O.

Mainor

T. M.

Duff

W. H.

(2001). Persistant pollutants in land-applied sludges. Nature 412, 140–41.

31.

Hamers

Kamstra

J. H.

Sonneveld

Murk

A. J.

Kester

M. H.

Andersson

P. L.

Legler

Brouwer

. (2006). In vitro profiling of the endocrine-disrupting potency of brominated flame retardants. Toxicol Sci 92, 157–73.

32.

Harley

K. G.

Marks

A. R.

Chevrier

Bradman

Sjodin

Eskenazi

(2010). PBDE concentrations in women's serum and fecundability. Environ Health Perspect 118, 699–704.

33.

Harper

M. E.

Seifert

E. L.

(2008). Thyroid hormone effects on mitochondrial energetics. Thyroid 18, 145–56.

34.

Harrad

Goosey

Desborough

Abdallah

M. A.

Roosens

Covaci

(2010). Dust from U.K. primary school classrooms and daycare centers: The significance of dust as a pathway of exposure of young U.K. children to brominated flame retardants and polychlorinated biphenyls. Environ Sci Technol 44, 4198–202.

35.

Hofland

van Weerden

W. M.

Dits

N. F.

Steenbergen

van Leenders

G. J.

Jenster

Schroder

F. H.

de Jong

F. H.

(2010). Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70, 1256–64.

36.

Hoppe

A. A.

Carey

G. B.

(2007). Polybrominated diphenyl ethers as endocrine disruptors of adipocyte metabolism. Obesity (Silver Spring) 15, 2942–50.

37.

Imaida

Wang

C. Y.

(1986). Effect of sodium phenobarbital and sodium saccharin in AIN-76A diet on carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and N,N-dibutylnitrosamine in male F344 rats. Cancer Res 46, 6160–64.

38.

Irizarry

R. A.

Ladd-Acosta

Wen

Montano

Onyango

Cui

Gabo

Rongione

Webster

Potash

J. B.

Sabunciyan

Feinberg

A. P.

(2009). The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41, 178–86.

39.

Irizarry

R. A.

Bolstad

B. M.

Collin

Cope

L. M.

Hobbs

Speed

T. P.

(2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31, e15.

40.

Jahnke

G. D.

Choksi

N. Y.

Moore

J. A.

Shelby

M. D.

(2004). Thyroid toxicants: Assessing reproductive health effects. Environ Health Perspect 112, 363–68.

41.

Jin

Yang

Hui

Liu

(2010). Cytotoxicity and apoptosis induction on RTG-2 cells of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) and decabrominated diphenyl ether (BDE-209). Toxicol In Vitro 24, 1190–96.

42.

Johnson

P. I.

Stapleton

H. M.

Sjodin

Meeker

J. D.

(2010). Relationships between polybrominated diphenyl ether concentrations in house dust and serum. Environ Sci Technol 44, 5627–32.

43.

Jorissen

R. N.

Lipton

Gibbs

Chapman

Desai

Jones

I. T.

Yeatman

T. J.

East

Tomlinson

I. P.

Verspaget

H. W.

Aaltonen

L. A.

Kruhoffer

Orntoft

T. F.

Andersen

C. L.

Sieber

O. M.

(2008). DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clin Cancer Res 14, 8061–69.

44.

Kleemann

R., M.

van Erk . (2010). Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PLoS One 5(1): e8817.

45.

Koliadi

Nilsson

Holmqvist

Holmberg

de La Torre

Warnberg

Fjallskog

M. L.

(2010). Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer. Acta Oncol 49, 816–20.

46.

Kupershmidt

Q. J.

Grewal

Sundaresh

Halperin

Flynn

Shekar

Wang

Park

Cui

Wall

G. D.

Wisotzkey

Alag

Akhtari

Ronaghi

(2010). Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One 5.

47.

Lee

M. H.

Hong

Kim

Lee

B. H.

Kim

J. H.

Kang

K. S.

Kim

H. L.

Yoon

B. I.

Chung

Kong

Lee

M. O.

(2008). Gene expression profiles of murine fatty liver induced by the administration of methotrexate. Toxicology 249, 75–84.

48.

Lee

M. H.

Kim

J. W.

Kim

J. H.

Kang

K. S.

Kong

Lee

M. O.

(2010). Gene expression profiling of murine hepatic steatosis induced by tamoxifen. Toxicol Lett 199, 416–24.

49.

Legler

Brouwer

(2003). Are brominated flame retardants endocrine disruptors? Environ Int 29, 879–85.

50.

Leigh-Brown

Enriquez

J. A.

Odom

D. T.

(2010). Nuclear transcription factors in mammalian mitochondria. Genome Biol 11, 215.

51.

Lim

J. S.

Lee

D. H.

Jacobs

D. R.,

Jr. (2008). Association of brominated flame retardants with diabetes and metabolic syndrome in the U.S. population, 2003–2004. Diabetes Care 31, 1802–7.

52.

Lopaschuk

G. D.

Ussher

J. R.

Folmes

C. D.

Jaswal

J. S.

Stanley

W. C.

(2010). Myocardial fatty acid metabolism in health and disease. Physiol Rev 90, 207–58.

53.

Lorber

(2008). Exposure of Americans to polybrominated diphenyl ethers. J Expo Sci Environ Epidemiol 18, 2–19.

54.

Lucero

Zago

Lopez

G. I.

Graffigna

Lopez

G. H.

Fainboim

Miksztowicz

Rosso

L. G.

Belli

Levalle

Berg

Brites

Wikinski

Schreier

(2011). Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clin Chim Acta 412, 587–92.

55.

Maronpot

Yoshizawa

Nyska

Harada

Flake

Muyeller

Singh

Ward

(2010). Hepatic enzyme induction: Histopathology. Toxicol Pathol 38, 776–95.

56.

Meerts

I. A.

Letcher

R. J.

Hoving

Marsh

Bergman

Lemmen

J. G.

van der Burg

Brouwer

. (2001). In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds. Environ Health Perspect 109, 399–407.

57.

Mercado-Feliciano

Bigsby

R. M.

(2008a). Hydroxylated metabolites of the polybrominated diphenyl ether mixture DE-71 are weak estrogen receptor-alpha ligands. Environ Health Perspect 116, 1315–21.

58.

Mercado-Feliciano

Bigsby

R. M.

(2008b). The polybrominated diphenyl ether mixture DE-71 is mildly estrogenic. Environ Health Perspect 116, 605–11.

59.

Miller

M. D.

Crofton

K. M.

Rice

D. C.

Zoeller

R. T.

(2009). Thyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes. Environ Health Perspect 117, 1033–41.

60.

N'Jai

Boverhof

D. R.

Dere

Burgoon

L. D.

Tan

Y. S.

Rowlands

J. C.

Budinsky

R. A.

Stebbins

K. E.

Zacharewski

T. R.

(2008). Comparative temporal toxicogenomic analysis of TCDD- and TCDF-mediated hepatic effects in immature female C57BL/6 mice. Toxicol Sci 103, 285–97.

61.

National Toxicology Program (2004). Bulk chemical comprehensive analysis report-technical pentabromodiphenyl oxide. Battelle Report 7-173-BCCA-24, December 31, 2003.

62.

National Toxicology Program (2005a). Three-month toxicity study of a pentabromodiphenyl oxide mixture (DE-71) administered by gavage to B6C3FI mice. Southern Research Institute Contract Report, Study number C20209, 11052.01.02 NTP Contract No. No1-ES-45516.

63.

National Toxicology Program (2005b). Three-month toxicity study of a pentabromodiphenyl oxide mixture (DE-71) administered by gavage to Fischer-344 rats. Southern Research Institute Contract Report, Study number C20209, 11052.01.02 NTP Contract No. N01-ES-45516.

64.

Nesnow

Ward

Moore

Ren

Hester

S. D.

(2009). Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression. Toxicol Sci 110, 68–83.

65.

Office of Laboratory Animal Welfare, National Institutes of Health, Department of Health and Human Services. U. S. Public Health Service Policy on Humane Care and Use of Laboratory Animals. http://grants.nih.gov/grants/olaw/olaw.htm#pol. Accessed April 2011.

66.

Pedrelli

Pramfalk

Parini

(2010). Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport. World J Gastroenterol 16, 5958–64.

67.

Petreas

She

Brown

F. R.

Winkler

Windham

Rogers

Zhao

Bhatia

Charles

M. J.

(2003). High body burdens of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) in California women. Environ Health Perspect 111, 1175–79.

68.

Rendic

Guengerich

F. P.

(2010). Update information on drug metabolism systems--2009, part I. Curr Drug Metab 11, 4–84.

69.

Richardson

V. M.

Staskal

D. F.

Ross

D. G.

Diliberto

J. J.

DeVito

M. J.

Birnbaum

L. S.

(2008). Possible mechanisms of thyroid hormone disruption in mice by BDE 47, a major polybrominated diphenyl ether congener. Toxicol Appl Pharmacol 226, 244–50.

70.

Rossi

Ravera

Repetti

Santi

(1977). Long-term administration of DDT or phenobarbital-Na in Wistar rats. Int J Cancer 19, 179–85.

71.

Roze

Meijer

Bakker

Van Braeckel

K. N.

Sauer

P. J.

Bos

A. F.

(2009). Prenatal exposure to organohalogens, including brominated flame retardants, influences motor, cognitive, and behavioral performance at school age. Environ Health Perspect 117, 1953–58.

72.

Saaf

A. M.

Halbleib

J. M.

Chen

Yuen

S. T.

Leung

S. Y.

Nelson

W. J.

Brown

P. O.

(2007). Parallels between global transcriptional programs of polarizing Caco-2 intestinal epithelial cells in vitro and gene expression programs in normal colon and colon cancer. Mol Biol Cell 18, 4245–60.

73.

Sanders

J. M.

Burka

L. T.

Smith

C. S.

Black

James

Cunningham

M. L.

(2005). Differential expression of CYP1A, 2B, and 3A genes in the F344 rat following exposure to a polybrominated diphenyl ether mixture or individual components. Toxicol Sci 88, 127–33.

74.

Schecter

Colacino

Sjodin

Needham

Birnbaum

(2010). Partitioning of polybrominated diphenyl ethers (PBDEs) in serum and milk from the same mothers. Chemosphere 78, 1279–84.

75.

Schecter

Papke

Harris

T. R.

Tung

K. C.

Musumba

Olson

Birnbaum

(2006). Polybrominated diphenyl ether (PBDE) levels in an expanded market basket survey of U.S. food and estimated PBDE dietary intake by age and sex. Environ Health Perspect 114, 1515–20.

76.

Sjodin

Jones

R. S.

Focant

J. F.

Lapeza

Wang

R. Y.

McGahee

E. E. I.

Zhang

Turner

W. E.

Slazyk

Needham

L. L.

Patterson

D. G.

Jr. (2004). Retrospective time trend study of polybrominate diphenyl ether and polybrominated and polychlorineated biphenyl levels in human serum form the United States. Environ Health Perspect 112, 654–58.

77.

Song

Murphy

M. B.

Yeung

L. W.

R. M.

Lam

M. H.

Lam

P. K.

Hecker

Giesy

J. P.

R. S.

Zhang

Sheng

(2008). Effects of fifteen PBDE metabolites, DE71, DE79 and TBBPA on steroidogenesis in the H295R cell line. Chemosphere 71, 1888–94.

78.

Stephens

P. J.

Greenman

C. D.

Yang

Bignell

G. R.

Mudie

L. J.

Pleasance

E. D.

Lau

K. W.

Beare

Stebbings

L. A.

McLaren

Lin

M. L.

McBride

D. J.

Varela

Nik-Zainal

Leroy

Jia

Menzies

Butler

A. P.

Teague

J. W.

Quail

M. A.

Burton

Swerdlow

Carter

N. P.

Morsberger

L. A.

Iacobuzio-Donahue

Follows

G. A.

Green

A. R.

Flanagan

A. M.

Stratton

M. R.

Futreal

P. A.

Campbell

P. J.

(2011). Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40.

79.

Stickel

Hellerbrand

(2010). Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: Mechanisms and implications. Gut 59, 1303–7.

80.

Suvorov

Takser

(2010). Global gene expression analysis in the livers of rat offspring perinatally exposed to low doses of 2,2′,4,4′-tetrabromodiphenyl ether. Environ Health Perspect 118, 97–102.

81.

Szabo

D. T.

Richardson

V. M.

Ross

D. G.

Diliberto

J. J.

Kodavanti

P. R.

Birnbaum

L. S.

(2009). Effects of perinatal PBDE exposure on hepatic phase I, phase II, phase III, and deiodinase 1 gene expression involved in thyroid hormone metabolism in male rat pups. Toxicol Sci 107, 27–39.

82.

Talsness

C. E.

Kuriyama

S. N.

Sterner-Kock

Schnitker

Grande

S. W.

Shakibaei

Andrade

Grote

Chahoud

. (2008). In utero and lactational exposures to low doses of polybrominated diphenyl ether-47 alter the reproductive system and thyroid gland of female rat offspring. Environ Health Perspect 116, 308–14.

83.

Tanaka

Arii

(2010). Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science. Int J Clin Oncol 15, 235–41.

84.

Teoh

N. C.

(2009). Proliferative drive and liver carcinogenesis: too much of a good thing? J Gastroenterol Hepatol 24, 1817–25.

85.

U.S. Environmental Protection Agency (2008a). Toxicological review of 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47). http://www.epa.gov/NCEA/iris/. Accessed April 2011.

86.

U.S. Environmental Protection Agency (2008b). Toxicological Review of 2,2′,4,4′,5,5′-hexabromodiphenyl ether (BDE-153). http://www.epa.gov/NCEA/iris/.

87.

U.S. Environmental Protection Agency (2008c). Toxicological Review of 2,2′.4,4′,5-pentabromodiphenyl ether (BDE-99). http://www.epa.gov/NCEA/iris/.

88.

U.S. Environmental Protection Agency (2008d). Toxicological Review of Decabromodiphenyl ether (BDE-209). http://www.epa.gov/NCEA/iris/.

89.

U.S. Environmental Protection Agency (2009). Chemical hazard review: furniture flame retardancy partnership: Environmental profiles of chemical flame-retardant alternatives for low-density polyurethane foam. http://www.epa.gov/dfe1.

90.

U.S. Environmental Protection Agency (2010). An exposure assessment of polybrominated diphenyl ethers. National Center for Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency, Washington, DC. http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=210404#Download.

91.

Waterman

C. L.

Currie

R. A.

Cottrell

L. A.

Dow

Wright

Waterfield

C. J.

Griffin

J. L.

(2010). An integrated functional genomic study of acute phenobarbital exposure in the rat. BMC Genomics 11, 9.

92.

World Health Organization (2003). Health risks of persistent organic pollutants from long-range transboundary air pollution. In pp. 199–212.

93.

Kerr

M. K.

Cui

X. Q.

Churchill

G. A.

(2003). MAANOVA: A software package for the analysis of spotted cDNA microarray experiments. In Analysis of Gene Expression Data: An Overview of Methods and Software ( Parmgiani

Garret

E. S.

Irizarry

R. A.

Zeger

S. L.

, eds.), pp. 313–41. Springer, New York, NY.

94.

Yang

Zhang

Molony

Chudin

Hao

Zhu

Gaedigk

Suver

Zhong

Leeder

J. S.

Guengerich

F. P.

Strom

S. C.

Schuetz

Rushmore

T. H.

Ulrich

R. G.

Slatter

J. G.

Schadt

E. E.

Kasarskis

Lum

P. Y.

(2010). Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res 20, 1020–36.

95.

Yanovski

S. Z.

Yanovski

J. A

. (2002). Obesity. N Engl J Med 346, 591–602.

96.

Zhou

Taylor

M. M.

DeVito

M. J.

Crofton

K. M.

(2002). Developmental exposure to brominated diphenyl etheres results in thyroid hormone disruption. Toxicol Sci 66, 105–16.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.01 MB

0.00 MB

2.53 MB

2.49 MB

0.03 MB

2.53 MB

0.05 MB

0.09 MB

Characterization of Polybrominated Diphenyl Ether Toxicity in Wistar Han Rats and Use of Liver Microarray Data for Predicting Disease Susceptibilities

Abstract

Keywords

Introduction

Materials and Methods

Chemical

Experimental Design

Necropsy and Collection of Liver Samples for Toxcogenomic Analysis

Liver Histopathology

RNA Preparation and Microarray Hybridization

Microarray Data Analysis

Data Normalization

Statistical Assessment of Differential Gene Expression

Gene Ontology Analyses

Comparison of Gene Transcript Expression to Human Disease

Results

Discussion

Footnotes

Abbreviations

References

Supplementary Material